MAVENCLAD, with the active ingredient cladribine, is a prescription medication used in the treatment of certain forms of multiple sclerosis (MS), specifically relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS) in adults. It is classified as a purine analog that works by suppressing the immune system, thereby reducing the frequency of relapse episodes and slowing the progression of the disease. MAVENCLAD is taken orally in the form of tablets and is notable for its short-course treatment regimen, typically involving two courses of treatment over two years, with no treatment required in the intervening months. This medication is generally recommended for patients who have not responded adequately to, or cannot tolerate, other treatments for MS. Due to its immune system effects, MAVENCLAD carries warnings about potential serious side effects, including risk of infections and malignancies, and requires careful patient selection and monitoring by healthcare professionals.